Nurix Therapeutics to Participate in the Jefferies Global Healthcare Conference
29 Maggio 2024 - 1:00PM
Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage
biopharmaceutical company developing targeted protein modulation
drugs designed to treat patients with cancer and inflammatory
diseases, today announced that Arthur T. Sands, M.D., Ph.D.,
president and chief executive officer of Nurix, will present a
corporate update at the Jefferies Global Healthcare Conference, at
5:30 p.m. ET on Wednesday, June 5, 2024, in New York City.
The event will be webcast live and may be accessed via a link in
the Investors section of the Nurix website under Events and
Presentations. The archived webcast will be available for 30 days
after the event.
About Nurix
Nurix Therapeutics is a clinical stage biopharmaceutical company
focused on the discovery, development and commercialization of
innovative small molecules and antibody therapies based on the
modulation of cellular protein levels as a novel treatment approach
for cancer, inflammatory conditions, and other challenging
diseases. Leveraging extensive expertise in E3 ligases together
with proprietary DNA-encoded libraries, Nurix has built DELigase,
an integrated discovery platform, to identify and advance novel
drug candidates targeting E3 ligases, a broad class of enzymes that
can modulate proteins within the cell. Nurix’s drug discovery
approach is to either harness or inhibit the natural function of E3
ligases within the ubiquitin-proteasome system to selectively
decrease or increase cellular protein levels. Nurix’s wholly owned,
clinical stage pipeline includes targeted protein degraders of
Bruton’s tyrosine kinase, a B-cell signaling protein, and
inhibitors of Casitas B-lineage lymphoma proto-oncogene B, an E3
ligase that regulates activation of multiple immune cell types
including T cell and NK cells. Nurix is headquartered in San
Francisco, California. For additional information
visit http://www.nurixtx.com.
Contacts:
Investors
Jason Kantor, Ph.D.Nurix Therapeuticsir@nurixtx.com
Elizabeth Wolffe, Ph.D.Wheelhouse Life Science
Advisorslwolffe@wheelhouselsa.com
Media
Aljanae ReynoldsWheelhouse Life Science
Advisorsareynolds@wheelhouselsa.com
Grafico Azioni Nurix Therapeutics (NASDAQ:NRIX)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni Nurix Therapeutics (NASDAQ:NRIX)
Storico
Da Set 2023 a Set 2024